Bayer Vital GmbH
Leverkusen, 51373, Germany
Location status: Recruiting
NCT Number: NCT07308639
The main goal of this study is to find out how common certain eye diseases are in Germany and how they have changed over time. The diseases being studied are:
nAMD (neovascular age-related macular degeneration): a condition that affects the central part of the retina and can cause vision loss in older adults.
DME (diabetic macular edema): a swelling in the central part of the retina caused by diabetes, which can also lead to vision problems.
RVO (retinal vein occlusion): a blockage of the veins in the retina, which can cause sudden vision loss.
Researchers will look at data collected from 2009 to 2024 to see how often these diseases occur (incidence) and how many people have them at a given time (prevalence). They will use two large sets of health data from Germany, called FDZ and FDGP.
The main question is: How do the numbers of new and existing cases of nAMD, DME, and RVO compare between the two data sources (FDZ and FDGP) in Germany from 2009 to 2024? The study also wants to find out if factors like age, other health problems, and medications affect how common these eye diseases are.
Another goal is to see how many people with these eye diseases are treated with a type of medicine called anti-VEGF, which is used to slow down or stop vision loss.
In summary, this study will help us understand how these eye diseases affect people in Germany, how they are treated, and whether different groups of people are more likely to get them.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Leverkusen, 51373, Germany
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
according to local label and treating physician
Time frame: 1 Jan 2009 - 31 Dec 2024
one-year incidence rate is defined as all new patients fulfilling the inclusion and exclusion criteria in each data repository in the respective year for the first time compared to all patients in the repository in the given year.
Time frame: 1 Jan 2009 - 31 Dec 2024
one-year prevalence rate is defined as the proportion of patients fulfilling inclusion and exclusion criteria in each data repository in the respective year PLUS patients identified in any previous year in relation to all patients in the repository in the given year.
Time frame: 1 Jan 2009 - 31 Dec 2024
one-year incidence rate is defined as all new patients fulfilling the inclusion and exclusion criteria in each data repository in the respective year for the first time compared to all patients in the repository in the given year.
Time frame: 1 Jan 2009 - 31 Dec 2024
one-year prevalence rate is defined as the proportion of patients fulfilling inclusion and exclusion criteria in each data repository in the respective year PLUS patients identified in any previous year in relation to all patients in the repository in the given year.
Time frame: 1 Jan 2009 - 31 Dec 2024
Time frame: 1 Jan 2009 - 31 Dec 2024
Contact information is provided by the study sponsor or research team.
Bayer
Industry
DATA-INSIGHT: Data Analysis for Treatment Assessment and Evaluation of New Sources for Evidence Generation in German Healthcare System
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01496625
Abnormalities, Multiple, Age-Related Macular Degeneration
Bethesda, Maryland, United States
View Trial DetailsNCT07205887
Branch Retinal Vein Occlusion (BRVO), Cardiovascular Diseases
Scottsdale, Arizona, United States
View Trial DetailsNCT04505618
Cardiovascular Diseases, Diabetes Complications
Baltimore, Maryland, United States
View Trial DetailsNCT03680794
Cardiovascular Diseases, Diabetes Complications
Reims, France
View Trial Details